フィブロバイオロジックス (FibroBiologics)、線維芽細胞ベースの治療薬を用いたミトコンドリア活性の調節に関する新規アプローチで特許申請
March 04, 2025 19:17 ET
|
Fibrobiologics, Inc.
この革新的な手法は、ミトコンドリアの機能異常が原因で起こる慢性疾患の新たな治療法につながる可能性が期待されている。 ヒューストン発 , March 05, 2025 (GLOBE NEWSWIRE) --...
FibroBiologics meldet Patent für neuartigen Ansatz zur Modulation mitochondrialer Aktivität mithilfe von auf Fibroblasten basierten Therapeutika an
March 04, 2025 19:17 ET
|
Fibrobiologics, Inc.
Diese innovative Methode hat das Potenzial, neue Behandlungsmöglichkeiten für chronische Erkrankungen zu erschließen, die durch mitochondriale Dysregulation verursacht werden. HOUSTON, March 05,...
FibroBiologics dépose une demande de brevet pour une nouvelle approche visant à moduler l’activité mitochondriale à l’aide de produits thérapeutiques à base de fibroblastes
March 04, 2025 19:17 ET
|
Fibrobiologics, Inc.
Cette nouvelle méthode pourrait ouvrir la voie vers de nouvelles options thérapeutiques ciblées sur des maladies chroniques causées par un dysfonctionnement mitochondrial. HOUSTON, 05 mars 2025 ...
FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics
March 04, 2025 08:30 ET
|
Fibrobiologics, Inc.
This innovative method has the potential to unlock new treatment options for chronic conditions driven by mitochondrial dysregulation. HOUSTON, March 04, 2025 (GLOBE NEWSWIRE) -- FibroBiologics,...
FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic
February 27, 2025 08:30 ET
|
Fibrobiologics, Inc.
HOUSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics") and Charles River Laboratories (“Charles River”), a leading, global provider of drug discovery,...
FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates
February 05, 2025 09:15 ET
|
Fibrobiologics, Inc.
HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing
December 30, 2024 16:30 ET
|
Fibrobiologics, Inc.
HOUSTON, Dec. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
FibroBiologics Announces $25 Million Financing
December 23, 2024 07:55 ET
|
Fibrobiologics, Inc.
HOUSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
November 19, 2024 09:15 ET
|
Fibrobiologics, Inc.
HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of...
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
November 14, 2024 09:15 ET
|
Fibrobiologics, Inc.
HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...